In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations

Publisher： Bentham Science Publishers

E-ISSN： 2212-389x|6|3|396-404

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.6, Iss.3, 2011-09, pp. : 396-404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : 662-669

John Wiley & Sons Inc

Access to resources Recommend Favorite

In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : 662-669

John Wiley & Sons Inc

Access to resources Recommend Favorite